BIO Submits Comments to FDA on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application
March 14, 2017
BIO submitted comments on the Food and Drug Administration’s draft guidance, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance for Industry.
BIO is committed to the effort to protect patients when biological products are handled in a manner that is inconsistent with their approved labeling and could result in contamination or a lack of effectiveness. BIO supports the FDA's efforts to release this draft guidance.
However, BIO believes some issues with respect to mixed, diluted, and repackaged biologics are not appropriately addressed in draft guidance or would benefit from additional clarification or refinement – such as the criticality of ensuring the sterility of the biological product’s primary container closure and its secondary packaging, which is essential to patient safety.
Download Full Comments Below
2017-3-14-17 BIO Comments On Revised Compounding Outside BLA FINAL
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
BIO submitted comments on the Food and Drug Administration’s draft guidance, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance for Industry.
BIO is committed to the effort to protect patients when biological products are handled in a manner that is inconsistent with their approved labeling and could result in contamination or a lack of effectiveness. BIO supports the FDA's efforts to release this draft guidance.
However, BIO believes some issues with respect to mixed, diluted, and repackaged biologics are not appropriately addressed in draft guidance or would benefit from additional clarification or refinement – such as the criticality of ensuring the sterility of the biological product’s primary container closure and its secondary packaging, which is essential to patient safety.